Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Int J Biol Macromol ; 232: 123400, 2023 Mar 31.
Article in English | MEDLINE | ID: mdl-36702230

ABSTRACT

Long non-coding RNA XIST promotes the development of various types of head and neck cancers, but its role in the progression of precancerous oral submucous fibrosis (OSF) has not been determined yet. As such, we aimed to examine whether XIST implicates in the regulation of myofibroblast activation. Our results showed that the expression of XIST was upregulated in OSF tissues and fibrotic buccal mucosal fibroblasts (fBMFs), and the silencing of XIST downregulated several myofibroblasts features. We demonstrated that elevation of let-7i after inhibition of XIST may lead to reduced myofibroblast activation. On the contrary, overexpression of high mobility group AT-Hook 1 (HMGA1) following the suppression of let-7i may result in enhanced myofibroblast activities. Moreover, we showed that the suppressive effect of silencing of XIST on myofibroblasts hallmarks was reversed by let-7i inhibition or HMGA1 overexpression, suggesting the pro-fibrotic property of XIST was mediated by downregulation of let-7i and upregulation of HMGA1. These findings revealed that myofibroblast activation of fBMFs may attribute to the alteration of the XIST/let-7i/HMGA1 axis. Therapeutic approaches to target this axis may serve as a promising direction to ameliorate the malignant progression of OSF.


Subject(s)
MicroRNAs , Oral Submucous Fibrosis , Humans , Oral Submucous Fibrosis/genetics , Oral Submucous Fibrosis/metabolism , Oral Submucous Fibrosis/pathology , Myofibroblasts/metabolism , HMGA1a Protein/genetics , HMGA1a Protein/metabolism , HMGA1a Protein/therapeutic use , Cell Movement , Mouth Mucosa/metabolism , Transcription Factors/metabolism , MicroRNAs/genetics
2.
J Immunol Res ; 2022: 4727198, 2022.
Article in English | MEDLINE | ID: mdl-35785026

ABSTRACT

Background: Tumor-associated macrophages (TAMs) are known to generate an immune-suppressive tumor microenvironment (TME) and promote tumor progression. Hepatocellular carcinoma (HCC) is a devastating disease that evolves in the background of chronic inflammatory liver damage. In this study, we aimed to uncover the mechanism by which HCC cells recruit macrophages into the TME. Methods: Bioinformatic analysis was performed to identify differentially expressed genes related to macrophage infiltration. An orthotopic HCC xenograft model was used to determine the role of macrophages in HCC tumor growth. Clodronate liposomes were used to delete macrophages. Western blotting analysis, quantitative real-time PCR, and enzyme-linked immunosorbent assay were performed to determine the underlying mechanisms. Results: The high mobility group A1 (HMGA1) gene was identified as a putative modulator of macrophage infiltration in HCC. Deletion of macrophages with clodronate liposomes significantly abrogated the tumor-promoting effects of HMGA1 on HCC growth. Mechanistically, HMGA1 can regulate the expression of C-C Motif Chemokine Ligand 2 (CCL2), also referred to as monocyte chemoattractant protein 1 (MCP1), which is responsible for macrophage recruitment. Moreover, NF-κB was required for HMGA1-mediated CCL2 expression. Pharmacological or genetic inhibition of NF-κB largely blocked CCL2 levels in HMGA1-overexpressing HCC cells. Conclusions: This study reveals HMGA1 as a crucial regulator of macrophage recruitment by activating NF-κB-CCL2 signaling, proves that HMGA1-induced HCC aggressiveness dependents on the macrophage, and provide an attractive target for therapeutic interventions in HCC.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Animals , Carcinoma, Hepatocellular/pathology , Chemokine CCL2/genetics , Chemokine CCL2/metabolism , Clodronic Acid/metabolism , Clodronic Acid/pharmacology , Clodronic Acid/therapeutic use , HMGA1a Protein/metabolism , HMGA1a Protein/therapeutic use , Humans , Ligands , Liposomes , Liver Neoplasms/pathology , Macrophages/metabolism , NF-kappa B/metabolism , Tumor Microenvironment
3.
J Orthop Surg Res ; 17(1): 246, 2022 Apr 22.
Article in English | MEDLINE | ID: mdl-35459188

ABSTRACT

BACKGROUND: miRNA-4701-5p has been reported to be a vital regulator in many diseases, including rheumatoid arthritis, and miRNA-4701-5p is evidenced to be participated in synovial invasion and joint destruction. In our report, we investigated the roles of miRNA-4701-5p in osteoarthritis (OA) and analyzed the molecular mechanism. METHODS: Interleukin-1ß (IL-1ß) was applied for stimulating human chondrocyte CHON-001 cells to establish an OA injury model. mRNA levels and protein expression were measured using qRT-PCR and western blot assay, respectively. The proliferation ability and cytotoxicity of CHON-001 cells were checked using MTT assay and lactate dehydrogenase activity. The inflammation of chondrocytes was accessed by the secretion levels of interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor (TNF)-α. The apoptosis of chondrocytes was determined by flow cytometry assay. Bioinformatics software Starbase v2.0 analyzed the functional binding sites between miRNA-4701-5p and HMGA1 and the interaction was further confirmed using dual luciferase reporter analysis. RESULTS: miRNA-4701-5p was down-regulated in the IL-1ß-stimulated chondrocytes and HMGA1 directly targeted miRNA-4701-5p. Up-regulation of miRNA-4701-5p could alleviate IL-1ß-treated CHON-001 cells inflammation and apoptosis, and reversed the cell proliferation decrease and cytotoxicity increase after IL-1ß treatment. Nevertheless, all the roles of miRNA-4701-5p overexpression in CHON-001 cells could be reversed by HMGA1 up-regulation. CONCLUSIONS: miRNA-4701-5p could alleviate the inflammatory injury of IL-1ß-treated CHON-001 cells via down-regulating HMGA1, indicating that miRNA-4701-5p/HMGA1 is a promising therapeutic target for OA.


Subject(s)
Chondrocytes , HMGA1a Protein , Interleukin-1beta , MicroRNAs , Osteoarthritis , Apoptosis , Chondrocytes/metabolism , HMGA1a Protein/genetics , HMGA1a Protein/immunology , HMGA1a Protein/metabolism , HMGA1a Protein/therapeutic use , Humans , Inflammation/metabolism , Interleukin-1beta/adverse effects , Interleukin-1beta/metabolism , MicroRNAs/genetics , MicroRNAs/immunology , MicroRNAs/metabolism , Osteoarthritis/etiology , Osteoarthritis/immunology , Osteoarthritis/metabolism , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL